Quick Answer
MiNK Therapeutics, Inc. reported Cash and Equivalents of $13.36 million for fiscal year 2025.
MiNK Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $13.36M | +191.9% |
| 2024 | $4.58M | +35.9% |
| 2023 | $3.37M | -82.9% |
| 2022 | $19.64M | -49.5% |
| 2021 | $38.89M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.28M | +125.7% | +749.1% |
| June 30, 2025 | $1.68M | -81.9% | -48.0% |
| March 31, 2025 | $3.23M | -44.4% | -29.3% |
| December 31, 2024 | $4.58M | +35.9% | -27.7% |
| September 30, 2024 | $6.33M | -1.1% | -32.1% |
| June 30, 2024 | $9.31M | -12.3% | +60.1% |
| March 31, 2024 | $5.82M | -60.9% | +72.8% |
| December 31, 2023 | $3.37M | -82.9% | -47.4% |
- MiNK Therapeutics, Inc. showed an increase of +191.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, MiNK Therapeutics, Inc.’s cash and equivalents has declined by 65.6% (from $38.89 million to $13.36 million).
- The most recent figure is from MiNK Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: